New genetic mapping studies explain why a certain mouse strain is predisposed to developing fatal leukemia. Turcotte et al., reporting on page 881, identify a point mutation in the transcription factor IRF-8 (interferon regulatory factor 8) that abolishes its function and sets the stage for a second, leukemia-triggering mutation.

FigureA mutation in IRF-8 causes myeloproliferation in the spleen which predisposes BXH-2 mice to leukemia.

The recombinant mouse strain BXH-2 is known to develop first a myeloproliferative disease characterized by enlarged spleens with excess granulocytes, and later a spontaneous, fatal myeloid leukemia. The myeloproliferative disease is associated with a mutation at the *Myls* locus on chromosome 8, and the leukemia with insertion of an endogenous murine leukemia virus (MuLV) into host tumor suppressor genes.

The offending virus arises from a recombination event between two innocuous MuLV proviruses; they are carried in the genome of BXH mice but, before recombination, cannot produce replicating virus progeny. Eager to understand how the viral integration event was connected to the *Myls* locus, Turcotte and colleagues scoured the locus for genetic clues. Their search revealed an inactivating point mutation in IRF-8, a transcription factor that regulates interferon-responsive genes. The mutation was found only in strains that are susceptible to getting leukemia.

The IRF-8 mutation explained the myeloproliferative disease in the BXH-2 mice, as IRF-8--deficient mice were previously shown to have a similar phenotype. IRF-8--deficient mice also develop leukemia, but it is not as rapid or as severe as in BXH-2 mice, perhaps because these strains lack the MuLV proviruses. The authors think that the absence of IRF-8 is only the first hit in leukemia development. The excess cell division and faulty immune response caused by the loss of IRF-8, they suggest, must promote recombination that generates a replication-competent MuLV retrovirus that can then insert into the host genome.This may be a good model for human chronic myeloid leukemia (CML), which progresses from a chronic phase involving granulocytes to a rapidly fatal crisis stage. The authors are now looking for the homologue of IRF-8 in human CML tumors.

[^1]: <hvanepps@rockefeller.edu>
